(Date:12/1/2008)...cal Incorporated (Nasdaq: VICL ) announced today...rom Merck & Co., Inc. based on Merck,s planned...stigational plasmid DNA (pDNA) cancer vaccine. The...livery technology and encodes human telomerase rev...f separate license agreement. , , "The brea...
(Date:11/28/2008)...- Eli Lilly and Company,(NYSE: LLY ) has withdr...rom,the U.S. Food and Drug Administration (FDA) f...t of chronic pain. Lilly plans to resubmit the app...rom a recently completed positive study,in chroni...cision does not affect duloxetine,s FDA-approved i...
(Date:11/26/2008)...KLIN, Mass., Nov. 26 PLC...d today that it has received full approval from th...U.S. pivotal trial to study the effectiveness of t... therapy in the prevention of Contrast-Induced Nep...LC,s request to expand their investigation from th...
(Date:11/25/2008)...re/ -- Proteolix, Inc., a,leader in the discovery...,protein degradation pathways in cancer and autoi...o ongoing Phase 2 clinical trials of carfilzomib i...ing 50th Annual Meeting of the,American Society o... new class,of specific proteasome inhibitors and ...
Breaking Medicine Technology:Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 2Proteolix to Present Clinical and Preclinical Data at the 50th Annual Meeting of the American Society of Hematology 3LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 1LI COR Biosciences and Euthanex Corporation Provide Anesthesia System for Small Animal Imaging 8527 2DFG continues to strengthen biodiversity research 5543 1DFG continues to strengthen biodiversity research 5543 2Innovative strategies for war wounded 5538 1Innovative strategies for war wounded 5538 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 1Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 2Field hospital on a chip project awarded to nanoengineer from UC San Diego 5536 3...lso Support Drug,s Efficacy at Improving Glycemic ...ications, CHICAGO, Ill., June 23, 2007 /PRNewswire...mercialization partner S2 Therapeutics,Inc., repo...trial,supporting the overall and cardiovascular sa...of bromocriptine mesylate) in subjects,with type 2...
...R CITY, Calif.--(BUSINESS WIRE)--June 25, 2007--Gi...that Study 103, a,Phase III clinical trial evaluat...R) (tenofovir disoproxil fumarate or tenofovir,DF)...itis B virus,(HBV) infection, met its primary effi...ferior to the company,s once-daily antiviral,drug ...
Other Medicine Technology:Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 2Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 3Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 4Phase IIIb Clinical Data Validate the Overall and Cardiovascular,Safety Profile of Cycloset (A Quick Release Formulation of,Bromocriptine Mesylate) in Patients with Type 2 Diabetes 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 2Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 3Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 4Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 5Second Phase III Study Evaluating Gilead's Viread for the Treatment,of Chronic Hepatitis B Virus Meets Primary Endpoint 6(Date:12/1/2008)...wire-USNewswire/ -- In recognition of World AIDS D...ching a mobile texting campaign to raise money for... a program of the Safe Blood for Africa Foundation...e million lives in Africa by 2011 by working in re...cal training. , , OMALI will be collecting...
(Date:12/1/2008)...RNewswire/ -- TOMS Shoes, the philanthropic,footw...e at TOMSshoes.com,encouraging people to Spend L...s, from November 20th through December 20th, TOMS ...irs of shoes to children in Ethiopia suffering,fr... by wearing shoes. By,purchasing a pair of shoes ...
(Date:12/1/2008)...rom U-M physician include economical options , ...SNewswire/ -- A bottle of cologne, a new pair of p...s to buy and wrap for the upcoming holiday season....y and beneficial to a loved one? Why not give the ... the holidays can be challenging, and this year, m...
(Date:12/1/2008)...swire/ -- TorreyPines Therapeutics, Inc.,(Nasdaq:... of NGX426, an,AMPA/kainate-type glutamate recept...ficant reduction in spontaneous pain, hyperalgesia...(pain resulting from normally non-painful stimuli ...ermal injections of capsaicin in,a human experime...
Breaking Medicine News(10 mins):Health News:In Recognition of WORLD AIDS DAY, Charlotte Bobcats' Power Forward, Emeka Okafor, Launches Mobile Texting Campaign in Support of the One Million African Lives Initiative 2Health News:TOMS Shoes Embarks on a Holiday Mission: Give 30,000 Pairs in 30 Days! 2Health News:Giving the Gift of Health This Holiday Season 2Health News:Giving the Gift of Health This Holiday Season 3Health News:Giving the Gift of Health This Holiday Season 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 2Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 3Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 4Health News:TorreyPines' NGX426, an Oral AMPA/Kainate Receptor Antagonist, Meets Primary Endpoints in Reducing Capsaicin-Induced Pain in Healthy Subjects 5...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
...Laboratories is a national reference laboratory an...arch and development. ARUP offers an extensive tes...in clinical and anatomic pathology. Owned by the U...ude more than half of the nation's university teac...
Medicine Products: